Monte Rosa Therapeutics GLUE Ratios (2021-2026)

NASDAQ GLUE
$13.84 -0.54 (-3.76%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Monte Rosa Therapeutics Quarterly Ratios

Periods 21 quarters
Latest Jun 2026

Monte Rosa Therapeutics reported a net margin of -483.91% for the quarter ended Jun 2026. These financial ratios cover 21 quarters of results from Jun 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin
-2,996.71%-640.21%-258.12%25.72%56.17%-7.91%-236.98%-1,656.81%-1,055.84%-481.59%
EBIT Margin
-3,284.49%-695.25%-287.84%21.44%51.85%-11.09%-258.26%-1,787.67%-1,188.46%-547.84%
EBITDA Margin
-3,284.49%-695.25%-287.84%21.44%51.85%-11.09%-258.26%-1,787.67%-1,188.46%-547.84%
Operating Margin
-3,284.49%-695.25%-287.84%21.44%51.85%-11.09%-258.26%-1,787.67%-1,188.46%-547.84%
Net Margin
-3,006.11%-645.58%-258.89%50.68%55.20%-8.77%-212.10%-1,399.64%-1,058.22%-483.91%
FCF Margin
-3,717.01%-634.48%-232.13%212.28%-55.43%-25.97%781.46%-1,574.29%-952.61%-534.89%
Efficiency
Assets AverageAssets Avg.
376.50M375.19M356.17M355.53M361.33M350.00M325.71M293.82M265.36M277.93M285.25M305.43M329.60M376.91M415.97M376.39M409.71M454.25M592.54M713.79M
Asset Utilization RatioAsset Util.
0.000.020.050.200.380.780.730.530.270.04
Valuation
Price to EarningsP/E
-52.16-21.84-27.07-17.06-14.47-12.19-12.00-9.66-6.87-8.52-11.06-7.57-18.2213.898.13-30.15-22.55-33.46-31.13-47.53
Price to SalesP/S
332.6248.8547.167.044.492.6447.82468.38329.48229.98
Price to BookP/B
2.801.472.011.491.361.381.581.591.301.582.321.022.121.911.391.382.485.592.664.23
Enterprise Value
668.63M164.43M515.46M347.78M281.85M110.53M331.72M292.68M180.76M46.87M254.16M120.52M309.09M45.90M302.64M301.23M208.94M913.62M709.00M1,429.58M
EV to EBIT
-33.65-7.03-21.21-12.77-9.94-3.40-9.68-7.86-4.89-1.34-7.27-3.69-11.653.536.87-19.37-6.34-18.38-14.17-29.10
EV to EBITDA
-33.65-7.03-21.21-12.77-9.94-3.40-9.68-7.86-4.89-1.34-7.27-3.69-11.653.536.87-19.37-6.34-18.38-14.17-29.10
Market Capitalization
1,035.66M510.50M653.76M451.44M395.21M375.35M384.52M339.71M239.81M283.29M353.91M229.37M434.66M426.86M381.17M370.66M610.57M1,302.56M1,387.09M2,062.48M
Price to FCFP/FCF
-52.98-29.63-22.47-19.58-17.96-12.02-11.80-10.67-9.1010.14-8.95-7.70-20.323.32-8.10-10.186.12-29.75-34.59-43.00
EV to FCF
-34.20-9.54-17.72-15.09-12.81-3.54-10.18-9.19-6.861.68-6.43-4.05-14.450.36-6.43-8.272.09-20.87-17.68-29.80
EV to CFO
-37.58-11.60-18.81-16.96-13.68-4.61-14.17-11.56-7.321.58-6.66-4.34-14.720.36-6.65-8.682.08-21.24-18.97-32.41
Return Ratios
Return on Sales [ROS]ROS
-3,284.49%-695.25%-287.84%21.44%51.85%-11.09%-258.26%-1,787.67%-1,188.46%-547.84%
Return on Capital Employed [ROCE]ROCE
-16.89%-20.33%-24.93%-27.82%-30.42%-34.64%-40.09%-48.17%-58.06%-61.95%-59.03%-52.99%-44.79%-36.88%-0.60%4.47%2.44%-13.90%-28.43%-27.80%
Return on Assets [ROA]ROA
-16.31%-19.41%-24.00%-26.40%-28.04%-31.06%-35.80%-42.65%-50.08%-48.70%-47.43%-42.70%-36.23%-14.70%5.64%11.02%9.33%-6.92%-20.73%-21.57%